fluoropharma medical inc (FPMI) Key Developments
FluoroPharma Medical, Inc. Appoints Andrew H. Sassine to its Board of Directors, Effective April 1, 2014
Mar 11 14
FluoroPharma Medical, Inc. announced the appointment of Andrew H. Sassine to the Board of Directors, effective April 1, 2014. Sassine brings a wealth of experience and credentials to the company. He served as a portfolio manager for Fidelity Investments until 2012. During his tenure, Mr. Sassine managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Sassine joined Fidelity in 1999 as a high yield research analyst covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank.
FluoroPharma Presents Data from Phase II Clinical Trial for (18) F-FCPHA
Feb 6 14
FluoroPharma Medical, Inc. announced the presentation of data from an ongoing Phase II clinical trial for (18) F-FCPHA (CardioPET) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients. Dr. Fabian Demeure, author of the abstract on the clinical trial, presented the data at the SNMMI Winter Meeting on February 6(th). The results are very encouraging for fatty acid imaging. (18) F-FCPHA was well tolerated and administered safely in study subjects at UC Louvain, part of a multi-center study in Belgium. (18) F FCPHA demonstrated rapid blood clearance with excellent image quality and image time was optimal; as early as 3 minutes post injection.
FluoroPharma Medical, Inc. Presents at Noble Financial Capital Markets Tenth Annual Equity Conference, Jan-20-2014 02:30 PM
Jan 15 14
FluoroPharma Medical, Inc. Presents at Noble Financial Capital Markets Tenth Annual Equity Conference, Jan-20-2014 02:30 PM. Venue: Club Med Sandpiper Bay Resort & Spa, Room One, 4500 SE Pine Valley Street, Port Saint Lucie, Florida, United States. Speakers: Johan M. Spoor, Chairman of the Board, Chief Executive Officer and President.
FluoroPharma Medical, Inc. Presents at 6th Annual LD Micro Conference, Dec-05-2013 11:30 AM
Nov 27 13
FluoroPharma Medical, Inc. Presents at 6th Annual LD Micro Conference, Dec-05-2013 11:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, CA 90049, United States. Speakers: Thijs Spoor, Chairman and CEO.
FluoroPharma Medical, Inc. Names Edward L. Lyons, Jr. to Newly Created Position of Vice President, Marketing
Oct 28 13
FluoroPharma Medical, Inc. announced that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to company's newly created position of Vice President, Marketing, effective October 28, 2013. Mr. Lyons will be responsible for the global development and commercial strategy for company's nuclear cardiology portfolio and will report directly to company's Chairman and CEO, Thijs Spoor. Prior to joining FluoroPharma, Mr. Lyons was with GE Healthcare where he held management positions of increasing responsibility, culminating in his appointment to Global Marketing Director, Nuclear Medicine, where he was responsible for the worldwide marketing of the general purpose, hybrid imaging and direct-conversion detector camera portfolios.